News Formal

A ranch that belongs to one of the founding families of Aspen just hit the market for $18 million — here's an inside look at the sprawling property

  • 📰 BusinessInsider
  • ⏱ Reading Time:
  • 17 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 10%
  • Publisher: 51%

France Nouvelles Nouvelles

France Dernières Nouvelles,France Actualités

Built in 2002, the $18 million ranch sits on 12 acres of mountainside property, just a 10-minute drive from the center of Aspen. Take a look inside.

While the main house was built in 2002, the Paepcke family has owned the land for 70 years. According to, the family began dividing the original 400 acres purchased by Walter Paepcke following his death in 1960.

Today, four lots remain — each around 12 acres — surrounding a 51-acre common area. The largest, his daughter's property, contains the Erickson Ranch mansion. Two of the other lots also feature residences built in the early 2000s, while the last one remains empty and is under construction for new development.

 

Merci pour votre commentaire. Votre commentaire sera publié après examen.
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

 /  🏆 729. in FR

France Dernières Nouvelles, France Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

Biogen scraps two Alzheimer drug trials, wipes $18 billion from market valueBiogen Inc and partner Eisai Co Ltd are ending two late-stage trials of their ex... I'll remember this. Why don’t they learn how to use CBDa? I take issue with the quote attributed to Guggenheim analyst, Yaris Suneja. You would not consider investment in Alzheimer ‘s research a “waste” if a loved one were so afflicted. This is a devastating disease. It takes a brave company to find an answer.
La source: Reuters - 🏆 2. / 97 Lire la suite »

Biogen scraps two Alzheimer drug trials, wipes $18 billion from market valueBiogen Inc and partner Eisai Co Ltd are ending two late-stage trials of their ex... I'll remember this. Why don’t they learn how to use CBDa? I take issue with the quote attributed to Guggenheim analyst, Yaris Suneja. You would not consider investment in Alzheimer ‘s research a “waste” if a loved one were so afflicted. This is a devastating disease. It takes a brave company to find an answer.
La source: Reuters - 🏆 2. / 97 Lire la suite »

Here's what could bring an end to the market's IPO high, according to one expertWall Street's reaction to money-losing companies like Lyft and Uber going public is a key factor in whether their valuations can hold up, says Renaissance Capital's Kathleen Smith.
La source: CNBC - 🏆 12. / 72 Lire la suite »